AI assistant
BOSTON SCIENTIFIC CORP — Director's Dealing 2020
Aug 31, 2020
29821_dirs_2020-08-31_33af7379-8e12-40ea-bb98-074020a5b64a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BOSTON SCIENTIFIC CORP (BSX)
CIK: 0000885725
Period of Report: 2020-08-28
Reporting Person: Nanavaty Maulik (SVP & Pres, Neuromodulation)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-08-28 | Common Stock | M | 6851.0000 | $17.2600 | Acquired | 266993.0000 | Direct |
| 2020-08-28 | Common Stock | S | 38000.0000 | $40.4517 | Disposed | 228993.0000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-08-28 | Stock Option (Right to Buy) | $17.2600 | M | 6851.0000 | Disposed | 2026-02-22 | Common Stock (6851.0000) | Direct |
Footnotes
F1: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
F2: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $40.44 to $40.47, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.